FISH mapping of Philadelphia negative BCR/ABL1 positive CML

Molecular Cytogenetics - Tập 1 Số 1 - 2008
Anna Virgili1, Diana Brazma1, Alistair Reid2, Julie Howard-Reeves1, Mikel Valgañón1, Anastasios Chanalaris1, Valeria Melo2, David Marín2, Jane F. Apperley2, Colin Grace1, E. Nacheva1
1Molecular Cytogenetics, Academic Haematology, Royal Free and UCL Medical School, Rowland Hill Street, London, NW3 2PF, UK
2Imperial College, Faculty Medicine, Dept of Haematology, Hammersmith Hospital, Du Cane Road, London, W12 ONN, UK

Tóm tắt

Abstract Background Chronic myeloid leukaemia (CML) is a haematopoietic stem cell disorder, almost always characterized by the presence of the Philadelphia chromosome (Ph), usually due to t(9;22)(q34;q11) or its variants. The Ph results in the formation of the BCR/ABL1 fusion gene, which is a constitutively activated tyrosine kinase. Around 1% of CML patients appear to have a Ph negative karyotype but carry a cryptic BCR/ABL1 fusion that can be located by fluorescence in situ hybridisation (FISH) at chromosome 22q11, 9q34 or a third chromosome. Here we present FISH mapping data of BCR and ABL1 flanking regions and associated chromosomal rearrangements in 9 Ph negative BCR/ABL1 positive CML patients plus the cell line CML-T1. Results BCR/ABL1 was located at 9q34 in 3 patients, 22q11 in 5 patients and CML-T1 and 22p11 in 1 patient. In 3 of 6 cases with the fusion at 22q11 a distal breakpoint cluster was found within a 280 Kb region containing the RAPGEF1 gene, while in another patient and the CML-T1 the distal breakpoint fell within a single BAC clone containing the 3' RXRA gene. Two cases had a duplication of the masked Ph while genomic deletions of the flanking regions were identified in 3 cases. Even more complex rearrangements were found in 3 further cases. Conclusion BCR/ABL1 formation resulted from a direct insertion (one step mechanism) in 6 patients and CML-T1, while in 3 patients the fusion gene originated from a sequence of rearrangements (multiple steps). The presence of different rearrangements of both 9q34 and 22q11 regions highlights the genetic heterogeneity of this subgroup of CML. Future studies should be performed to confirm the presence of true breakpoint hot spots and assess their implications in Ph negative BCR/ABL1 positive CML.

Từ khóa


Tài liệu tham khảo

Melo JV, Barnes DJ: Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007, 7: 441–53. 10.1038/nrc2147

Hagemeijer A, de Klein A, Godde-Salz E, Turc-Carel C, Smit EM, van Agthoven AJ, Grosveld GC: Translocation of c-abl to "masked" Ph in chronic myeloid leukemia. Cancer Genet Cytogenet 1985, 18: 95–104. 10.1016/0165-4608(85)90059-7

Morris CM, Reeve AE, Fitzgerald PH, Hollings PE, Beard ME, Heaton DC: Genomic diversity correlates with clinical variation in Ph'-negative chronic myeloid leukaemia. Nature 1986, 320: 281–3. 10.1038/320281a0

Hagemeijer A, Buijs A, Smit E, Janssen B, Creemers GJ, Plas D, Grosveld G: Translocation of BCR to chromosome 9: a new cytogenetic variant detected by FISH in two Ph-negative, BCR-positive patients with chronic myeloid leukemia. Genes Chromosomes Cancer 1993, 8: 237–45. 10.1002/gcc.2870080406

Nacheva E, Holloway T, Brown K, Bloxham D, Green AR: Philadelphia-negative chronic myeloid leukaemia: detection by FISH of BCR-ABL fusion gene localized either to chromosome 9 or chromosome 22. Br J Haematol 1994, 87: 409–12. 10.1111/j.1365-2141.1994.tb04933.x

Morris CM, Heisterkamp N, Kennedy MA, Fitzgerald PH, Groffen J: Ph-negative chronic myeloid leukemia: molecular analysis of ABL insertion into M-BCR on chromosome 22. Blood 1990, 76: 1812–8.

Valle L, Fernandez V, Perez-Pons C, Sanchez FG, Benitez J, Urioste M: Generation of the BCR/ABL fusion gene in a Philadelphia chromosome-negative chronic myeloid leukaemia: insertion of 5.6 Mb of 9q34 into the BCR region of chromosome 22. Hematol Oncol 2006, 24: 86–8. 10.1002/hon.775

Zagaria A, Anelli L, Albano F, Vicari L, Schiavone EM, Annunziata M, Pane F, Liso V, Rocchi M, Specchia G: Molecular cytogenetic characterization of deletions on der(9) in chronic myelocytic leukemia. Cancer Genet Cytogenet 2006, 167: 97–102. 10.1016/j.cancergencyto.2006.01.011

Storlazzi CT, Anelli L, Surace C, Lonoce A, Zagaria A, Nanni M, Curzi P, Rocchi M: Molecular cytogenetic characterization of a complex rearrangement involving chromosomes 9 and 22 in a case of Ph-negative chronic myeloid leukemia. Cancer Genet Cytogenet 2002, 136: 141–5. 10.1016/S0165-4608(02)00530-7

Todoric-Zivanovic B, Marisavljevic D, Surace C, Cemerikic V, Markovic O, Krtolica K, Tatomirovic Z, Cikota B, Magic Z, Rocchi M: A Ph-negative chronic myeloid leukemia with a complex BCR/ABL rearrangement and a t(6;9)(p21;q34.1). Cancer Genet Cytogenet 2006, 166: 180–5. 10.1016/j.cancergencyto.2005.11.008

Kuriyama K, Gale RP, Tomonaga M, Ikeda S, Yao E, Klisak I, Whelan K, Yakir H, Ichimaru M, Sparkes RS, Dreazen O: CML-T1: a cell line derived from T-lymphocyte acute phase of chronic myelogenous leukemia. Blood 1989, 74: 1381–7.

Gribble SM, Reid AG, Roberts I, Grace C, Green AR, Nacheva EP: Genomic imbalances in CML blast crisis: 8q24.12-q24.13 segment identified as a common region of over-representation. Genes Chromosomes Cancer 2003, 37: 346–58. 10.1002/gcc.10173

De Melo VA, Milojkovic D, Marin D, Apperley JF, Nacheva EP, Reid AG: Deletions adjacent to BCR and ABL1 breakpoints occur in a substantial minority of chronic myeloid leukemia patients with masked Philadelphia rearrangements. Cancer Genet Cytogenet 2008, 182: 111–5. 10.1016/j.cancergencyto.2008.01.007

UCSC Human Genome Browser Gateway[http://genome.ucsc.edu]

Human 32K BAC Re-Array[http://bacpac.chori.org/genomicRearrays.php]

Spectral Genomics[http://www.spectralgenomics.com]

Agilent[http://www.agilent.com]

Brazma D, Grace C, Howard J, Melo JV, Holyoke T, Apperley JF, Nacheva EP: Genomic profile of chronic myelogenous leukemia: Imbalances associated with disease progression. Genes Chromosomes Cancer 2007, 46: 1039–50. 10.1002/gcc.20487

Molecular Cytogenetics of Haematological Disorders[http://www.ucl.ac.uk/leukemia-cytogenetics]

Guerrero C, Fernandez-Medarde A, Rojas JM, Font de Mora J, Esteban LM, Santos E: Transformation suppressor activity of C3G is independent of its CDC25-homology domain. Oncogene 1998, 16: 613–24. 10.1038/sj.onc.1201569

Guerrero C, Martin-Encabo S, Fernandez-Medarde A, Santos E: C3G-mediated suppression of oncogene-induced focus formation in fibroblasts involves inhibition of ERK activation, cyclin A expression and alterations of anchorage-independent growth. Oncogene 2004, 23: 4885–93. 10.1038/sj.onc.1207622

Cho YJ, Hemmeryckx B, Groffen J, Heisterkamp N: Interaction of Bcr/Abl with C3G, an exchange factor for the small GTPase Rap1, through the adapter protein Crkl. Biochem Biophys Res Commun 2005, 333: 1276–83. 10.1016/j.bbrc.2005.06.030

Ahuja HS, Szanto A, Nagy L, Davies PJ: The retinoid × receptor and its ligands: versatile regulators of metabolic function, cell differentiation and cell death. J Biol Regul Homeost Agents 2003, 17: 29–45.

Taschner S, Koesters C, Platzer B, Jorgl A, Ellmeier W, Benesch T, Strobl H: Down-regulation of RXRalpha expression is essential for neutrophil development from granulocyte/monocyte progenitors. Blood 2007, 109: 971–9. 10.1182/blood-2006-04-020552

Zhu J, Nasr R, Peres L, Riaucoux-Lormiere F, Honore N, Berthier C, Kamashev D, Zhou J, Vitoux D, Lavau C, de The H: RXR is an essential component of the oncogenic PML/RARA complex in vivo. Cancer Cell 2007, 12: 23–35. 10.1016/j.ccr.2007.06.004

Zeisig BB, Kwok C, Zelent A, Shankaranarayanan P, Gronemeyer H, Dong S, So CW: Recruitment of RXR by homotetrameric RARalpha fusion proteins is essential for transformation. Cancer Cell 2007, 12: 36–51. 10.1016/j.ccr.2007.06.006

Sinclair PB, Nacheva EP, Leversha M, Telford N, Chang J, Reid A, Bench A, Champion K, Huntly B, Green AR: Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 2000, 95: 738–43.

Huntly BJ, Reid AG, Bench AJ, Campbell LJ, Telford N, Shepherd P, Szer J, Prince HM, Turner P, Grace C, Nacheva EP, Green AR: Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 2001, 98: 1732–8. 10.1182/blood.V98.6.1732

Huntly BJ, Guilhot F, Reid AG, Vassiliou G, Hennig E, Franke C, Byrne J, Brizard A, Niederwieser D, Freeman-Edward J, Cuthbert G, Bown N, Clark RE, Nacheva EP, Green AR, Deininger MW: Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood 2003, 102: 2205–12. 10.1182/blood-2002-09-2763

Quintas-Cardama A, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Rios MB, Hayes K, Glassman A, Bekele BN, Zhou X, Cortes J: Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood 2005, 105: 2281–6. 10.1182/blood-2004-06-2208

Kreil S, Pfirrmann M, Haferlach C, Waghorn K, Chase A, Hehlmann R, Reiter A, Hochhaus A, Cross NC: Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia. Blood 2007, 110: 1283–90. 10.1182/blood-2007-02-074252

Batista DA, Hawkins A, Murphy KM, Griffin CA: BCR/ABL rearrangement in two cases of Philadelphia chromosome negative chronic myeloid leukemia: deletion on the derivative chromosome 9 may or not be present. Cancer Genet Cytogenet 2005, 163: 164–7. 10.1016/j.cancergencyto.2005.04.021

Costa D, Espinet B, Queralt R, Carrio A, Sole F, Colomer D, Cervantes F, Hernandez JA, Besses C, Campo E: Chimeric BCR/ABL gene detected by fluorescence in situ hybridization in three new cases of Philadelphia chromosome-negative chronic myelocytic leukemia. Cancer Genet Cytogenet 2003, 141: 114–9. 10.1016/S0165-4608(02)00662-3

Dufva IH, Karle H, Brondum-Nielsen K, Andersen MK, Madsen HO, Johnsen HE: Chronic myeloid leukaemia with BCR-ABL fusion genes located to both chromosomes 9, cyclic leukocytosis and nodal T-lymphoblastic transformation–durable complete remission following imatinib therapy. Leukemia 2005, 19: 671–3.

Fugazza G, Garuti A, Marchelli S, Miglino M, Bruzzone R, Gatti AM, Castello S, Sessarego M: Masked Philadelphia chromosome due to atypical BCR/ABL localization on the 9q34 band and duplication of the der(9) in a case of chronic myelogenous leukemia. Cancer Genet Cytogenet 2005, 163: 173–5. 10.1016/j.cancergencyto.2005.05.010

Thông tin
Thông tin xuất bản

Molecular Cytogenetics

Tập 1 Số 1

Thông tin tác giả